Edition:
United States

Apollo Endosurgery Inc (APEN.OQ)

APEN.OQ on NASDAQ Stock Exchange Global Market

6.52USD
22 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.52
Open
$6.61
Day's High
$6.75
Day's Low
$6.52
Volume
3,665
Avg. Vol
33,253
52-wk High
$14.09
52-wk Low
$3.60

Chart for

About

Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company's device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80... (more)

Overall

Beta: 0.50
Market Cap(Mil.): $112.73
Shares Outstanding(Mil.): 17.29
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 50.18 16.52
EPS (TTM): -- -- --
ROI: -- 14.12 36.19
ROE: -- 16.71 17.38

BRIEF-Apollo Endosurgery Announces MFDS Approval For Orbera Intragastric Balloon System

* APOLLO ENDOSURGERY ANNOUNCES MFDS APPROVAL FOR ORBERA INTRAGASTRIC BALLOON SYSTEM IN SOUTH KOREA, A NON-SURGICAL SOLUTION TO ASSIST PATIENTS WITH WEIGHT LOSS Source text for Eikon: Further company coverage:

Feb 22 2018

BRIEF-Apollo Endosurgery Inc Files For Stock Shelf Of Upto $50 Million - SEC Filing ‍​

* APOLLO ENDOSURGERY INC FILES FOR STOCK SHELF OF UPTO $50 MILLION - SEC FILING ‍​ Source text (http://bit.ly/2AONduG) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Dec 04 2017

BRIEF-Apollo Endosurgery Receives FDA Clearance For Overstitch Sx Endoscopic Suturing System

* APOLLO ENDOSURGERY RECEIVES FDA CLEARANCE FOR OVERSTITCH™ SX ENDOSCOPIC SUTURING SYSTEM

Nov 27 2017

BRIEF-David Pacitti joins Apollo Endosurgery board of directors

* David C. Pacitti joins Apollo Endosurgery board of directors

Nov 16 2017

BRIEF-Apollo Endosurgery reports qtrly loss per share $‍0.32​

* Apollo Endosurgery Inc - qtrly loss per share $‍0.32​ Source text for Eikon: Further company coverage:

Oct 26 2017

BRIEF-Apollo endosurgery announces CE mark approval for the Orbera365™ managed weight loss system,

* Apollo Endosurgery announces CE mark approval for the Orbera365™ managed weight loss system, expanding the indwell period from 6 months to 12 months with the gastric balloon category leader

Aug 30 2017

Earnings vs. Estimates